文献速递妇产影像骨肌儿科影像USCT

超声联合循环游离胎儿DNA分析优化无创诊断胎儿软骨发育不全

Optimal non-invasive diagnosis of fetal achondroplasia combining ultrasonography with circulating cell-free fetal DNA analysis.
PubMed 文献 · Ultrasound Obstet Gynecol · 2018-11-28

前瞻性多中心研究纳入86例高危孕妇和65例低危对照,采用高分辨率熔解曲线分析联合SNaPshot微测序检测cffDNA中FGFR3两种主要突变,无创产前检测敏感度和特异度均为1.00。作者提出将cffDNA分析与超声联合用于软骨发育不全的无创诊断策略。

要点

  • cffDNA检测FGFR3两种主要突变的敏感度1.00(95%CI 0.87-1.00),特异度1.00(95%CI 0.96-1.00)。
  • 受累胎儿股骨长关键性缩短自孕26周起可观察到。
  • 作者提出将cffDNA分析与超声联合用于软骨发育不全的无创诊断策略。

核心结论

  • 高分辨率熔解曲线分析联合SNaPshot微测序是软骨发育不全无创产前检测的可靠方法。
  • 将其与超声联合应用于常规临床实践是软骨发育不全无创诊断的有效策略。

研究设计与样本

  • 前瞻性多中心研究,采集86例有胎儿软骨发育不全风险的孕妇血液样本和65例低危对照血液样本。
  • 从孕妇血液中提取cffDNA,采用高分辨率熔解曲线分析检测FGFR3两种主要突变,并以SNaPshot微测序确认。
  • 结果与三维CT或出生后检查获得的表型及/或侵入性操作的分子诊断相比较。
  • 分析胎儿生物测量(头围和股骨长),以制定仅在选定病例中提供cffDNA分析诊断软骨发育不全的策略。

关键影像表现/征象

  • 受累胎儿股骨长关键性缩短自孕26周起可观察到。

诊断标准与关键数值

  • 无创产前检测诊断软骨发育不全的总体敏感度为1.00(95%CI 0.87-1.00),特异度为1.00(95%CI 0.96-1.00)。

临床应用与阅片要点

  • 作者提出将cffDNA分析与超声联合用于软骨发育不全的无创诊断策略。
  • 胎儿股骨长关键性缩短自孕26周起可观察到,可作为超声筛查的参考时间点。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To assess the performance of non-invasive prenatal testing (NIPT) for achondroplasia using high-resolution melting (HRM) analysis, and to propose an optimal diagnostic strategy combining ultrasound examination and cell-free fetal DNA (cffDNA) analysis.

METHODS: In this prospective multicenter study, cffDNA was extracted from blood of pregnant women at risk for fetal achondroplasia (owing to paternal achondroplasia, previous affected child or suspected rhizomelic shortening) and of pregnant low-risk controls. The presence of either one of the two main fibroblast growth factor receptor 3 gene (FGFR3) mutations was determined using HRM combined with confirmation by SNaPshot minisequencing. Results were compared with phenotypes obtained using three-dimensional computed tomography or postnatal examination, and/or molecular diagnosis by an invasive procedure. Fetal biometry (head circumference and femur length) was analyzed in order to develop a strategy in which cffDNA analysis for diagnosis of achondroplasia is offered only in selected cases.

RESULTS: Eighty-six blood samples from women at risk for fetal achondroplasia and 65 from controls were collected. The overall sensitivity and specificity of NIPT were 1.00 (95% CI, 0.87-1.00) and 1.00 (95% CI, 0.96-1.00), respectively. Critical reduction in femur length of affected fetuses could be observed from 26 weeks' gestation.

CONCLUSIONS: HRM combined with SNaPshot minisequencing is a reliable method for NIPT for achondroplasia. Its implementation in routine clinical care combined with ultrasonography is an efficient strategy for the non-invasive diagnosis of achondroplasia. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Vivanti AJ, Costa JM, Rosefort A, et al. Optimal non-invasive diagnosis of fetal achondroplasia combining ultrasonography with circulating cell-free fetal DNA analysis. Ultrasound Obstet Gynecol. 2018. PMID: 29380944. doi:10.1002/uog.19018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。